Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Type (CMT1B), 2A (CMT2A), 4A (CMT4A), 4C (CMT4C), and Others
| City: |
|
Rochester |
| State: |
|
New York |
| Zip Code: |
|
14642 |
| Conditions: |
|
Charcot Marie Tooth Disease |
| Purpose: |
|
This is an observational longitudinal study to determine the natural history and
genotype-phenotype correlations of disease causing mutations in Charcot Marie Tooth disease
(CMT) type 1B (CMT1B), 2A (CMT2A), 4A (CMT4A), and 4C (CMT4C).
The investigators will also be determine the capability of the newly developed CMT Pediatric
Scale (CMT Peds scale) and the Minimal Dataset to measure impairment and perform
longitudinal measurements in patients with multiple forms of CMT over a five year window
|
| Study Summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
All patients MUST be seen in person at a participating clinical site to be enrolled in the
study.
Inclusion Criteria - Charcot Marie Tooth disease type 1B (CMT1B) and type 2A (CMT2A)
1. Patient has documented, disease causing mutation in the MPZ gene (for CMT1B) or in
MFN2 (for CMT2A) OR
2. Patient has a first or second degree family member (parent, child, sibling,
half-sibling, aunt, uncle, grandparent, or grandchild) with a documented disease
causing mutation AND a clear link between that family member and the affected patient
AND a phenotype consistent with the diagnosis
- A clear link is necessary for a second-degree relative. For example, if a
grandparent is affected and has a disease causing mutation, and the parent does
not have any signs, symptoms, or electrophysiology consistent with the
diagnosis, there is no clear link.
- In cases where clear links are not available, genetic testing is required for
the patient or the family member who is not clearly affected.
3. Patients who have a variant of uncertain significance, as determined by the
laboratory performing the testing may still be included if one of the following
circumstances applies:
- Variant is listed as disease causing at
http://www.molgen.ua.ac.be/CMTMutations/Mutations/Default.cfm.
- Variant has been found in multiple affected people in a family and has not been
found in unaffected family members. (Note - both affected and unaffected family
members must be tested in this situation to be included).
4. Patient has understood and signed an IRB approved consent form for the study.
Teenagers (age 13 - 17 years) must sign an assent form. See Appendix A for a sample
consent form with HIPAA. See Appendix B for a sample assent form.
Inclusion Criteria - Charcot Marie Tooth disease type 4A (CMT4A) and 4C (CMT4C)
1. Patient has two documented, disease causing mutations in the GDAP1 gene (for CMT4A)
or two mutations in the SH3TC2 gene (for CMT4C) OR
2. Patients who have variants of uncertain significance, as determined by the laboratory
performing the testing, may still be included if one of the following circumstances
applies:
- Patient has one known disease causing mutation and one variant that is listed as
disease causing at
http://www.molgen.ua.ac.be/CMTMutations/Mutations/Default.cfm.
OR
- Patient has two variants listed as disease causing mutations at the above
website.
OR
- Patient is homozygous for a variant with or without consanguineous parents. OR
- The principal investigator and the site investigator agree that the variant(s)
is (are) most likely disease causing.
3. Patient has understood and signed an IRB approved consent form for the study.
Teenagers (age 13 - 17 years) must sign an assent form.
ADDITIONAL PARTICIPANTS
For patients with other forms of CMT than listed above, we will perform all assessments to
prepare for further studies into the disease and the disease process. These patients will
be characterized based on their type of CMT, if known, or by the following categories:
- Nerve conduction velocities: demyelinating , axonal, intermediate
- Inheritance: dominant, recessive, X-linked, or unknown
Exclusion Criteria:
1. Patient does not have a documented mutation in MPZ (for CMT1B) or MFN2 (for CMT2A),
nor does a first or second degree family member. Patient does not have two documented
mutations in GDAP1 (for CMT4A) or SH3TC2 (CMT4C).
2. Patient has a variant of uncertain significance that cannot be further classified
following methods listed in the Inclusion Criteria.
3. Patient does not wish to be a part of the study or has not signed an informed consent
form.
4. Patient is deemed inappropriate by the Site PI.
|
| NCT ID: |
|
NCT01193075 |
| Primary Contact: |
|
Principal Investigator
Michael E Shy, MD
Wayne State University
Carly E Siskind, MS
Phone: 313-577-8317
Email: csiskind@med.wayne.edu
|
| Backup Contact: |
|
Email: lrowe@med.wayne.edu
Lisa Rowe, BS
Phone: 313-577-1689
|
| Location Contact: |
|
Rochester, New York 14642
United States
Janet Sowden
Phone: 585-275-1267
Email: janet_sowden@urmc.rochester.edu
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
June 18, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|